An observational study in Fever of Unknown Origin, Inflammation of Unknown Origin and Fever, sponsored by University of Adelaide. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by University of Adelaide · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Retrospective cohort study of inpatients at a South Australian tertiary hospital who underwent 18F FDG-PET/CT for investigation of undifferentiated fever or inflammatory syndrome. The aim is to investigate the utility of FDG-PET/CT in the investigation of suspected infection in hospitalised adults. To establish the rate at which FDG-PET/CT contributes to a diagnosis, and how this impacts clinical management and outcomes. From this, to develop further understanding of for which patients this imaging modality contributes meaningfully to outcomes.
A retrospective cohort study of consecutive adult inpatients undergoing 18F-FDG PET/CT for suspected infection or inflammation, excluding infective endocarditis and malignancy-directed scans. Pre-PET variables include inflammatory markers, microbiological results, prior imaging findings and infectious diseases (ID) consultation. PET/CT utility will be adjudicated as diagnostic and/or associated with a change in management using a structured consensus process. Associations between pre-PET factors and clinical utility will be explored using descriptive and logistic analyses.
21 studies on the registry are indexed under Fever of Unknown Origin; 2 are open to participants now.
This study's enrollment of 266 is above the median of 100 across 11 observational studies indexed under Fever of Unknown Origin.
Browse Fever of Unknown Origin studies →University of Adelaide is the lead sponsor of 42 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive adults referred for FDG-PET/CT for evaluation of undifferentiated fever, inflammation or infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 18F-FDG PET/CT
Diagnostic Test: 18F-FDG PET/CT
Nuclear medicine imaging as a diagnostic tool with implication for change in clinical management
Diagnostic yield
• Did PET contribute to diagnostic yield?: * 1 = Yes: PET led to a finding either definitive e.g. confirmed by gold standard (microbiology, histopathology, intraoperative findings etc) or contributory, which guided diagnosis or management even without gold standard confirmation. Examples of contributory: PET showing vascular graft uptake, not explanted due to risk but presumptively treated Vertebral discitis suggested by PET, biopsied without culture, but presumptively treated and clinically improved PET negative - antibiotics ceased, patient remained well * 0 = No: PET provided no new information, was misleading (i.e. PET result contradicted by later results), or no action was taken based on PET
Time frame: 30 days
Clinical change in management
• Clinical change in management: was clinical care altered compared to the documented plan prior to PET? 0 = no, 1 = yes * Yes: antimicrobial therapy, procedures/interventions (PET-guided site biopsy, or surgery/drainage), diagnostics e.g. further focussed imaging, or disposition e.g. palliative care transition * No: there was no change to the management plan, or the plan was already determined by other data Examples: * PET confirmed a suspected diagnosis but the treatment plan was unchanged * PET provided supporting evidence but no explicit management adjustment was documented * PET was negative and no further management steps were taken because there was a pre-existing plan
Time frame: 30 days
Change in antimicrobial management
•Change in antimicrobial duration/spectrum/therapeutic procedure: this change occurred as a result of PET
Time frame: 30 days
Final diagnosis
• Final diagnosis: infection = 1, non-infectious = 2, malignancy = 3, unresolved = 4
Time frame: 30 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Jan 2024, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Adelaide